Matthew Berry, Bill Carmody and Jacob Buchdahl represented Aragon Pharmaceuticals in a breach of contract action in the San Francisco Superior Court. They teamed up to defeat the efforts of Medivation, a $3.5 billion dollar pharmaceutical company, in order to secure exclusive rights for their client to develop a promising prostate cancer drug.
The legal team persuaded the San Francisco Superior Court to grant summary adjudication in favor of their client, Aragon, on December 20. Medivation had valued the drug at more than $200 million.
